Aytu BioPharma, Inc.(AYTU)Earnings, Financials & Key Ratios
AYTU•NASDAQ
$2.56
$16M mkt cap·Price updated May 6, 2026
AboutAytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.Show more
- Revenue$66M+1.8%
- EBITDA-$2M-147.7%
- Net Income-$14M+14.4%
- EPS (Diluted)-2.16+24.5%
- Gross Margin69.04%-8.3%
- EBITDA Margin-3.69%-146.9%
- Operating Margin-11.79%-383.1%
- Net Margin-20.43%+15.9%
- ROE-58.1%-23.0%
- ROIC-33.47%-894.7%
- Debt/Equity1.21+104.2%
- Interest Coverage-2.11-536.6%
AYTU Key Insights
Aytu BioPharma, Inc. (AYTU) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 19.2%
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 13.4% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AYTU Price & Volume
Aytu BioPharma, Inc. (AYTU) stock price & volume — 10-year historical chart
Loading chart...
AYTU Growth Metrics
Aytu BioPharma, Inc. (AYTU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years73.94%
5 Years19.16%
3 Years-11.78%
TTM-3.33%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-366.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-164.64%
Return on Capital
10 Years-70.95%
5 Years-35.52%
3 Years-13.29%
Last Year-13.3%
AYTU Peer Comparison
Aytu BioPharma, Inc. (AYTU) competitors in Specialty pharma brand consolidators — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 TPVG | 225.54M | 5.57 | 4.57 | 36.55% | 13.09% | 1.33 | ||
 ASRT | 142.57M | 22.20 | -4.68 | -5% | -24.85% | -29.39% | 0.42 | |
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 COLL | 1.18B | 36.51 | 21.10 | 23.62% | 8.05% | 24.11% | 3.12 | |
 JAZZ | 14.34B | 228.57 | -39.14 | 4.88% | 0.66% | 0.71% | 1.26 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 TEVA | 42.31B | 36.34 | 30.28 | 4.31% | 9.02% | 20.69% | 2.20 |
Compare AYTU vs Peers
Aytu BioPharma, Inc. (AYTU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AYTU Income Statement
Aytu BioPharma, Inc. (AYTU) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 3.22M | 3.66M | 7.32M | 27.63M | 65.63M | 96.67M | 107.4M | 65.18M | 66.38M | 62.64M |
| Revenue Growth % | 25.72% | 13.61% | 100.01% | 277.47% | 137.52% | 47.29% | 11.1% | -39.31% | 1.84% | -3.33% |
| Cost of Goods Sold | 1.42M | 2.05M | 2.2M | 8.28M | 36.43M | 46.39M | 40.77M | 16.13M | 20.55M | 21.3M |
| COGS % of Revenue | 44% | 56.03% | 30.08% | 29.97% | 55.51% | 47.98% | 37.96% | 24.74% | 30.96% | - |
| Gross Profit | 1.8M▲ 0% | 1.61M▼ 10.8% | 5.12M▲ 218.0% | 19.35M▲ 278.1% | 29.2M▲ 50.9% | 50.28M▲ 72.2% | 66.63M▲ 32.5% | 49.05M▼ 26.4% | 45.83M▼ 6.6% | 41.34M▲ 0% |
| Gross Margin % | 56% | 43.97% | 69.92% | 70.03% | 44.49% | 52.02% | 62.04% | 75.26% | 69.04% | 66% |
| Gross Profit Growth % | 12.39% | -10.8% | 218.02% | 278.07% | 50.9% | 72.2% | 32.51% | -26.38% | -6.57% | - |
| Operating Expenses | 20.66M | 19.45M | 21.96M | 40.48M | 88.07M | 160.19M | 83.7M | 50.65M | 53.66M | 50.02M |
| OpEx % of Revenue | 641.43% | 531.51% | 300.05% | 146.5% | 134.19% | 165.71% | 77.93% | 77.7% | 80.83% | - |
| Selling, General & Admin | 17.61M | 17.73M | 19.24M | 31.06M | 55.81M | 69.88M | 70.08M | 42.04M | 38.28M | 39.09M |
| SG&A % of Revenue | 546.55% | 484.48% | 262.82% | 112.41% | 85.03% | 72.29% | 65.25% | 64.49% | 57.67% | - |
| Research & Development | 1.35M | 167.59K | 589.07K | 1.72M | 5.62M | 12.66M | 4.09M | 2.77M | 1.33M | 378K |
| R&D % of Revenue | 41.84% | 4.58% | 8.05% | 6.23% | 8.57% | 13.1% | 3.81% | 4.25% | 2% | - |
| Other Operating Expenses | 1.71M | 6.28M | 2.14M | 7.7M | 26.64M | 77.65M | 9.52M | 5.84M | 14.05M | 2.36M |
| Operating Income | -20.13M▲ 0% | -19.7M▲ 2.1% | -16.85M▲ 14.5% | -21.13M▼ 25.4% | -58.87M▼ 178.6% | -109.91M▼ 86.7% | -17.07M▲ 84.5% | -1.59M▲ 90.7% | -7.83M▼ 392.0% | -8.68M▲ 0% |
| Operating Margin % | -624.7% | -538.26% | -230.13% | -76.47% | -89.7% | -113.69% | -15.89% | -2.44% | -11.79% | -13.85% |
| Operating Income Growth % | 7.28% | 2.11% | 14.49% | -25.43% | -178.6% | -86.69% | 84.47% | 90.68% | -391.95% | - |
| EBITDA | -18.28M | -17.85M | -14.61M | -15.42M | -49.67M | -99.76M | -8.25M | 5.13M | -2.45M | -4.38M |
| EBITDA Margin % | -567.5% | -487.77% | -199.59% | -55.79% | -75.68% | -103.2% | -7.68% | 7.88% | -3.69% | -6.99% |
| EBITDA Growth % | 12.23% | 2.35% | 18.16% | -5.52% | -222.17% | -100.85% | 91.73% | 162.23% | -147.72% | -143.84% |
| D&A (Non-Cash Add-back) | 1.84M | 1.85M | 2.24M | 5.71M | 9.2M | 10.15M | 8.81M | 6.72M | 5.38M | 4.3M |
| EBIT | -19.97M | -17.84M | -16.85M | -17.92M | -38.24M | -38.1M | -12.09M | -5.32M | -10.04M | -21.54M |
| Net Interest Income | -2.53M | -749.42K | 0 | 0 | 0 | -147.48M | -4.96M | -4.79M | -3.7M | -2.71M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 14K | 0 | 0 | 0 | 0 |
| Interest Expense | 2.53M | 749.42K | 0 | 0 | 0 | 147.5M | 4.96M | 4.79M | 3.7M | 2.71M |
| Other Income/Expense | -2.38M | 9.51M | -10.29M | 7.51M | 840K | 1.02M | 14K | -8.79M | -5.92M | -15.57M |
| Pretax Income | -22.51M▲ 0% | -10.19M▲ 54.7% | -27.13M▼ 166.3% | -13.62M▲ 49.8% | -58.03M▼ 326.0% | -108.89M▼ 87.6% | -17.05M▲ 84.3% | -10.38M▲ 39.1% | -13.74M▼ 32.4% | -24.24M▲ 0% |
| Pretax Margin % | -698.67% | -278.36% | -370.64% | -49.29% | -88.42% | -112.64% | -15.88% | -15.92% | -20.71% | -38.7% |
| Income Tax | 0 | 0 | 20.04M | 0 | 259K | -110K | 0 | 2.14M | 437K | 315K |
| Effective Tax Rate % | 0% | 0% | -73.84% | 0% | -0.45% | 0.1% | 0% | -20.64% | -3.18% | -1.3% |
| Net Income | -22.51M▲ 0% | -10.19M▲ 54.7% | -47.17M▼ 363.0% | -13.62M▲ 71.1% | -58.29M▼ 327.9% | -108.78M▼ 86.6% | -17.05M▲ 84.3% | -15.84M▲ 7.1% | -13.56M▲ 14.4% | -24.44M▲ 0% |
| Net Margin % | -698.67% | -278.36% | -644.33% | -49.29% | -88.81% | -112.53% | -15.88% | -24.31% | -20.43% | -39.02% |
| Net Income Growth % | 20.13% | 54.74% | -362.97% | 71.12% | -327.93% | -86.62% | 84.33% | 7.08% | 14.4% | -366.29% |
| Net Income (Continuing) | -22.51M | -10.19M | -27.13M | -13.62M | -58.29M | -108.78M | -17.05M | -12.52M | -14.18M | -24.56M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.32M | 620K | 116K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -193194.38▲ 0% | -3061.23▲ 98.4% | -1210.28▲ 60.5% | -60.20▲ 95.0% | -69.60▼ 15.6% | -74.01▼ 6.3% | -5.11▲ 93.1% | -2.86▲ 44.0% | -2.16▲ 24.5% | -2.44▲ 0% |
| EPS Growth % | 85.08% | 98.42% | 60.46% | 95.03% | -15.61% | -6.34% | 93.1% | 44.03% | 24.48% | -164.64% |
| EPS (Basic) | -193194.38 | -3061.23 | -1210.28 | -60.20 | -69.60 | -74.01 | -5.11 | -2.86 | -2.16 | - |
| Diluted Shares Outstanding | 117 | 3.33K | 38.97K | 230K | 840K | 1.47M | 3.34M | 5.54M | 6.28M | 10.04M |
| Basic Shares Outstanding | 117 | 3.33K | 38.97K | 230K | 840K | 1.47M | 3.34M | 5.54M | 6.28M | 10.04M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AYTU Balance Sheet
Aytu BioPharma, Inc. (AYTU) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.03M | 9.47M | 15.43M | 75.42M | 105.23M | 59.93M | 72.83M | 61.89M | 79.18M | 76.24M |
| Cash & Short-Term Investments | 802.33K | 7.01M | 11.04M | 48.08M | 49.65M | 19.36M | 22.98M | 20.01M | 30.95M | 30.02M |
| Cash Only | 802.33K | 7.01M | 11.04M | 48.08M | 49.65M | 19.36M | 22.98M | 20.01M | 30.95M | 30.02M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 528.04K | 578.78K | 1.74M | 5.63M | 28.18M | 21.71M | 28.94M | 23.53M | 31.16M | 30.92M |
| Days Sales Outstanding | 59.83 | 57.72 | 86.8 | 74.41 | 156.7 | 81.98 | 98.34 | 131.74 | 171.31 | 191.02 |
| Inventory | 1.31M | 1.34M | 1.44M | 10M | 16.34M | 10.85M | 11.99M | 12.14M | 11.43M | 8.66M |
| Days Inventory Outstanding | 337.93 | 238.34 | 238.7 | 440.72 | 163.69 | 85.37 | 107.4 | 274.75 | 203.08 | 176.74 |
| Other Current Assets | 75.21K | 100K | 250K | 5.99M | 1.29M | 633K | 868K | 1.12M | 0 | 0 |
| Total Non-Current Assets | 11.97M | 11.59M | 19.29M | 77.87M | 160.43M | 77.69M | 65.01M | 56.97M | 45M | 45.76M |
| Property, Plant & Equipment | 647.25K | 219K | 203.73K | 893K | 8.7M | 6.3M | 3.87M | 1.52M | 1.59M | 1.44M |
| Fixed Asset Turnover | 4.98x | 16.71x | 35.93x | 30.94x | 7.54x | 15.35x | 27.76x | 42.83x | 41.67x | 40.39x |
| Goodwill | 238.43K | 0 | 0 | 28.09M | 65.8M | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 11.08M | 11.37M | 19.08M | 48.85M | 85.46M | 70.63M | 58.97M | 52.45M | 42.2M | 43.58M |
| Long-Term Investments | 0 | 0 | 0 | 0 | -10.91M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.89K | 4.72K | 2.2K | 33K | 465K | 766K | 792K | 2.23M | 1.2M | 4.2M |
| Total Assets | 15M▲ 0% | 21.06M▲ 40.4% | 34.72M▲ 64.9% | 153.29M▲ 341.5% | 265.67M▲ 73.3% | 137.62M▼ 48.2% | 137.84M▲ 0.2% | 118.86M▼ 13.8% | 124.18M▲ 4.5% | 122M▲ 0% |
| Asset Turnover | 0.21x | 0.17x | 0.21x | 0.18x | 0.25x | 0.70x | 0.78x | 0.55x | 0.53x | 0.51x |
| Asset Growth % | -38.39% | 40.41% | 64.87% | 341.49% | 73.31% | -48.2% | 0.16% | -13.77% | 4.48% | 13.73% |
| Total Current Liabilities | 3.61M | 3.39M | 5.37M | 28.76M | 109.44M | 64.44M | 69.02M | 62.23M | 63.06M | 65.56M |
| Accounts Payable | 2.22M | 2.12M | 2.13M | 11.64M | 19.25M | 10.99M | 13.48M | 10.31M | 10.6M | 14.26M |
| Days Payables Outstanding | 571.8 | 377.3 | 353.64 | 513.05 | 192.91 | 86.45 | 120.67 | 233.41 | 188.28 | 211 |
| Short-Term Debt | 0 | 0 | 0 | 982K | 24.6M | 3.81M | 8.74M | 4.96M | 10.92M | 11.13M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 339.34K | 57.23M | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.05M | 734.43K | 2.23M | 8M | 1.47M | 23.84M | 41.12M | 42.35M | 26.14M | 37.88M |
| Current Ratio | 0.84x | 2.79x | 2.87x | 2.62x | 0.96x | 0.93x | 1.06x | 0.99x | 1.26x | 1.26x |
| Quick Ratio | 0.48x | 2.40x | 2.60x | 2.27x | 0.81x | 0.76x | 0.88x | 0.80x | 1.07x | 1.07x |
| Cash Conversion Cycle | -174.05 | -81.25 | -28.15 | 2.08 | 127.48 | 80.89 | 85.07 | 173.08 | 186.1 | 156.76 |
| Total Non-Current Liabilities | 7.39M | 4.24M | 22.26M | 29.52M | 18.66M | 28.87M | 29.47M | 28.91M | 42.15M | 42.24M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 2.8M | 14.2M | 20.86M | 10.88M | 10.89M | 10.97M |
| Capital Lease Obligations | 0 | 0 | 0 | 725K | 2.62M | 84K | 832K | 577K | 985K | 3.98M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 11.15M | 0 | 1.38M | 762K | 0 | 0 |
| Other Non-Current Liabilities | 7.39M | 4.24M | 22.26M | 28.79M | 13.23M | 14.59M | 6.4M | 16.7M | 30.27M | 91.95M |
| Total Liabilities | 11M | 7.64M | 27.63M | 58.28M | 128.1M | 93.31M | 98.48M | 91.14M | 105.21M | 107.8M |
| Total Debt | 0 | 0 | 0 | 2.01M | 30.97M | 18.19M | 30.43M | 16.42M | 22.94M | 23.07M |
| Net Debt | -802.33K | -7.01M | -11.04M | -46.08M | -18.68M | -1.17M | 7.44M | -3.59M | -8.02M | -6.95M |
| Debt / Equity | - | - | - | 0.02x | 0.23x | 0.41x | 0.77x | 0.59x | 1.21x | 1.21x |
| Debt / EBITDA | - | - | - | - | - | - | - | 3.20x | - | -5.27x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -0.70x | - | 1.59x |
| Interest Coverage | -7.94x | -26.29x | - | - | - | -0.75x | -3.44x | -0.33x | -2.11x | -7.96x |
| Total Equity | 4M▲ 0% | 13.42M▲ 235.6% | 7.09M▼ 47.2% | 95.02M▲ 1240.5% | 137.57M▲ 44.8% | 44.31M▼ 67.8% | 39.36M▼ 11.2% | 27.72M▼ 29.6% | 18.97M▼ 31.6% | 14.2M▲ 0% |
| Equity Growth % | -60.34% | 235.63% | -47.2% | 1240.54% | 44.79% | -67.79% | -11.17% | -29.58% | -31.57% | -94.33% |
| Book Value per Share | 34331.42 | 4033.78 | 181.87 | 413.11 | 163.77 | 30.14 | 11.78 | 5.00 | 3.02 | 1.41 |
| Total Shareholders' Equity | 4M | 13.42M | 7.09M | 95.02M | 137.57M | 44.31M | 39.36M | 27.72M | 18.97M | 14.2M |
| Common Stock | 82 | 179 | 1.75K | 1K | 3K | 0 | 1K | 1K | 1K | 1K |
| Retained Earnings | -69.07M | -79.26M | -106.39M | -120.01M | -178.3M | -287.08M | -304.13M | -319.97M | -333.54M | -342.15M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -246K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AYTU Cash Flow Statement
Aytu BioPharma, Inc. (AYTU) cash flow — operating, investing & free cash flow history
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -13.83M | -15.94M | -13.83M | -28.37M | -25.96M | -28.82M | -5.13M | -1.39M | -1.94M | -1.94M |
| Operating CF Margin % | -429.28% | -435.53% | -188.94% | -102.68% | -39.56% | -29.82% | -4.78% | -2.13% | -2.92% | - |
| Operating CF Growth % | -29.77% | -15.26% | 13.23% | -105.14% | 8.49% | -11.01% | 82.21% | 72.94% | -39.55% | -1911.05% |
| Net Income | -22.51M | -10.19M | -27.13M | -13.62M | -58.29M | -108.78M | -17.05M | -15.84M | -13.56M | -24.44M |
| Depreciation & Amortization | 4.36M | 2.59M | 2.73M | 6.25M | 9.2M | 10.15M | 8.81M | 6.72M | 5.38M | 4.46M |
| Stock-Based Compensation | 2.5M | 348.51K | 1.02M | 1.08M | 3.57M | 5.25M | 6.05M | 2.37M | 576K | 536K |
| Deferred Taxes | 1.62M | -1.94M | -80.78K | 573.53K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.23M | -6.03M | 9.84M | -10.04M | 17.87M | 75.42M | 2.86M | 10.02M | 11.4M | 23.07M |
| Working Capital Changes | -1.04M | -718.81K | -210.2K | -12.61M | 1.68M | -10.86M | -5.8M | -4.66M | -5.73M | -4.16M |
| Change in Receivables | -355.03K | -50.74K | -1.16M | -3.56M | 1.54M | 6.53M | -7.15M | 5.2M | -7.63M | -5.6M |
| Change in Inventory | 195.43K | -26.75K | -101.1K | -6.95M | 2.79M | 1.3M | -3.61M | -4.82M | 382K | 1.09M |
| Change in Payables | 493.22K | -109.71K | 134.78K | -1.38M | -3.25M | -7.68M | 2.38M | -2.08M | 287K | -384K |
| Cash from Investing | -3.53M | -484.29K | -1.06M | -5.66M | -2.78M | -3.25M | -117K | -329K | -2.56M | -3.1M |
| Capital Expenditures | -111.61K | -74.71K | -59.85K | 0 | 0 | 0 | 0 | -329K | -228K | -3.1M |
| CapEx % of Revenue | 3.46% | 2.04% | 0.82% | - | - | - | - | 0.5% | 0.34% | - |
| Acquisitions | -4.04M | -7.38K | -505.02K | 188.23K | -481K | -3.18M | -5K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 613.31K | -402.2K | -497.11K | -5.84M | -2.3M | -70K | -112K | 0 | -2.33M | 0 |
| Cash from Financing | 10.19M | 22.66M | 19.08M | 71.07M | 30.31M | 1.53M | 8.87M | -1.26M | 15.44M | 13.32M |
| Debt Issued (Net) | 0 | 0 | 5M | -16.25M | -3.74M | -5.22M | -2.35M | -1.89M | 6.67M | -262K |
| Equity Issued (Net) | 1000K | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 845.19K | -2.08M | 14.08M | -44.14M | -6.09M | -4.94M | -4.36M | -2.84M | -6.07M | -1.25M |
| Net Change in Cash | -7.18M▲ 0% | 6.23M▲ 186.9% | 4.18M▼ 32.9% | 37.04M▲ 785.7% | 1.57M▼ 95.8% | -30.54M▼ 2047.8% | 3.63M▲ 111.9% | -2.98M▼ 182.2% | 10.95M▲ 467.4% | 9.63M▲ 0% |
| Free Cash Flow | -13.94M▲ 0% | -16.02M▼ 14.9% | -13.89M▲ 13.3% | -28.37M▼ 104.3% | -25.96M▲ 8.5% | -28.82M▼ 11.0% | -5.13M▲ 82.2% | -1.72M▲ 66.5% | -5.17M▼ 200.8% | -698K▲ 0% |
| FCF Margin % | -432.74% | -437.57% | -189.76% | -102.68% | -39.56% | -29.82% | -4.78% | -2.63% | -7.78% | -1.11% |
| FCF Growth % | -7.98% | -14.88% | 13.26% | -104.26% | 8.49% | -11.01% | 82.21% | 66.52% | -200.82% | -445.54% |
| FCF per Share | -119661.30 | -4812.17 | -356.44 | -123.36 | -30.91 | -19.61 | -1.54 | -0.31 | -0.82 | -0.82 |
| FCF Conversion (FCF/Net Income) | 0.61x | 1.56x | 0.29x | 2.08x | 0.45x | 0.26x | 0.30x | 0.09x | 0.14x | 0.03x |
| Interest Paid | 0 | 0 | 0 | 0 | 1.25M | 3.15M | 3.81M | 4.04M | 2.82M | 1.64M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.61M | 1.42M | 140K |
AYTU Key Ratios
Aytu BioPharma, Inc. (AYTU) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -319.61% | -116.94% | -459.89% | -26.68% | -50.12% | -119.62% | -40.76% | -47.24% | -58.1% | -172.12% |
| Return on Invested Capital (ROIC) | -577.37% | -307.51% | -1029.09% | -70.46% | -52.62% | -101.75% | -28.46% | -3.36% | -33.47% | -33.47% |
| Gross Margin | 56% | 43.97% | 69.92% | 70.03% | 44.49% | 52.02% | 62.04% | 75.26% | 69.04% | 66% |
| Net Margin | -698.67% | -278.36% | -644.33% | -49.29% | -88.81% | -112.53% | -15.88% | -24.31% | -20.43% | -39.02% |
| Debt / Equity | - | - | - | 0.02x | 0.23x | 0.41x | 0.77x | 0.59x | 1.21x | 1.21x |
| Interest Coverage | -7.94x | -26.29x | - | - | - | -0.75x | -3.44x | -0.33x | -2.11x | -7.96x |
| FCF Conversion | 0.61x | 1.56x | 0.29x | 2.08x | 0.45x | 0.26x | 0.30x | 0.09x | 0.14x | 0.03x |
| Revenue Growth | 25.72% | 13.61% | 100.01% | 277.47% | 137.52% | 47.29% | 11.1% | -39.31% | 1.84% | -3.33% |
AYTU Frequently Asked Questions
Aytu BioPharma, Inc. (AYTU) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aytu BioPharma, Inc. (AYTU) reported $62.6M in revenue for fiscal year 2025.
Aytu BioPharma, Inc. (AYTU) grew revenue by 1.8% over the past year. Growth has been modest.
Aytu BioPharma, Inc. (AYTU) reported a net loss of $24.4M for fiscal year 2025.
Dividend & Returns
Aytu BioPharma, Inc. (AYTU) has a return on equity (ROE) of -58.1%. Negative ROE indicates the company is unprofitable.
Aytu BioPharma, Inc. (AYTU) had negative free cash flow of $0.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More AYTU
Aytu BioPharma, Inc. (AYTU) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates